UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE
ACT OF 1934
For the month of March 2026
Commission File Number: 001-37384
GALAPAGOS NV
(Translation of registrant's name
into English)
Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium
(Address of principal executive
office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F
[ X ] Form 40-F [ ]
The information contained in this Report on Form 6-K, including Exhibit 99.1, except for the quotes of Henry Gosebruch and Tania Philipp, included in Exhibit 99.1, is hereby incorporated by reference into the Company's
Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333- 218160, 333-225263, 333-231765, 333-249416,
333-260500, 333-268756, 333-275886, 333-283361, and 333-292050).
On March 5, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein
by reference.
Exhibit 99.1. Press release dated March 5, 2026
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.
| |
|
GALAPAGOS NV |
| |
|
(Registrant) |
| |
|
|
| |
|
|
| Date: March 5, 2026 |
|
/s/ Annelies Denecker |
| |
|
Annelies Denecker |
| |
|
Company Secretary |
| |
|
|
EXHIBIT 99.1
Galapagos Appoints Tania Philipp as Chief Human Resources Officer
Seasoned Life Sciences Executive Joins Galapagos with Strong Track Record in Change Management
Mechelen, Belgium; March 5, 2026, 22:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG) today announced the
appointment of Tania Philipp as Chief Human Resources Officer (CHRO), effective March 4, 2026. Ms. Philipp will also join the Management
Committee. She succeeds Annelies Missotten, who will remain with the company through June 30, 2026, to ensure a smooth transition.
Ms. Philipp brings nearly three decades of experience as an executive-level human resources leader supporting the vision,
mission and objectives of life sciences companies. Most recently, she served as an Executive Human Resources Consultant at Vor Bio, following
several years as Chief People Officer and Vice President, Head of People, supporting the organization through key phases of development.
Prior to that, she held HR leadership roles including Vice President, Human Resources at Tango Therapeutics, and senior HR roles at Bavarian
Nordic and other life science organizations. Ms. Philipp holds an M.A. in Psychology from the University of the Pacific and attended Hollins
University.
“We are delighted to welcome Tania to Galapagos,” said Henry Gosebruch, CEO of Galapagos. “Tania
brings a proven ability to build strong cultures within early-stage life sciences organizations undergoing transformation. She will play
a critical role as we build a high-performing, purpose-driven culture at Galapagos focused on brining meaningful medicines to patients.”
Gosebruch continued: “I also want to thank Annelies for her outstanding leadership and contributions during her
time at Galapagos. I am grateful that we will continue to benefit from her experience and leadership over the next several months as we
continue to execute our transformation.”
“I am excited to join Galapagos at this important moment in the Company’s evolution,” said Ms. Philipp.
“I look forward to partnering with the leadership team to further strengthen our culture and ensure we are well positioned to execute
our strategy and deliver meaningful value for patients and shareholders.”
About Galapagos
Galapagos is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic
areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities
that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational
flexibility, Galapagos prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging
areas. For more information, visit www.glpg.com or follow us on LinkedIn or X.
For further information, contact Galapagos:
Investor Relations
Glenn Schulman
+1 412 522 6239
ir@glpg.com
Media
Media
Katie Morris
+1 952 288 6821
katiemorris@ententeinc.com
Visit us at www.glpg.com or follow us on LinkedIn or X.
Forward-looking statements
This press release may include forward-looking statements, all
of which involve certain risks and uncertainties. These statements are often, but not always, made through the use of words or phrases
such as “will,” “long-term,” and “forward,” and any similar expressions. These statements
include, but are not limited to, statements regarding the announced leadership transition and changes in our Management Committee and
key personnel; Mr. Philipp’s expected responsibilities and potential contributions to the company, and the company’s strategic
formation. Any forward-looking statements in this press release are based on our management’s current expectations and beliefs
and are not guarantees of future performance. Forward-looking statements may involve unknown and known risks, uncertainties, and other
factors which might cause our actual results, performance, or achievements to be materially different from any historic or future
results, performance, or achievements expressed or implied by such statements. These risks, uncertainties, and other factors
include, without limitation, the risk that Galapagos will encounter challenges retaining or attracting talent, that our leadership
transition may be disruptive to our business operations, and risks related to our ability to effectively transfer knowledge during this
period of transition. A further list and description of these risks, uncertainties, and other factors can be found in our filings
and reports with the Securities and Exchange Commission (SEC), including in our most recent annual report on Form 20‐F filed with
the SEC, as supplemented and/or modified by any other filings and reports that we have made or will make with the SEC in the future. Given
these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition,
even if our results, performance, or achievements are consistent with such forward-looking statements, they may not be predictive
of results, performance, or achievements in future periods. These forward-looking statements speak only as of the date of publication
of this press release. We expressly disclaim any obligation to update any forward-looking statements in this press release, unless
required by law or regulation.
